奥沙利铂联合表柔比星经导管动脉栓塞化疗治疗原发性肝癌的临床疗效  

Clinical efficacy of oxaliplatin combined with epirubicin transcatheter arterial chemoembolization in the treatment of primary liver cancer

作　　者：张栋华[1] 周晓鲁[1] 魏涛[1] ZHANG Donghua;ZHOU Xiaolu;WEI Tao(Department of Infectious Disease,the Fifth People’s Hospital of Anyang,Anyang 455000,He’nan,China)

机构地区：[1]安阳市第五人民医院传染科,河南安阳4550000

出　　处：《癌症进展》2022年第9期959-961,共3页Oncology Progress

摘　　要：目的探讨奥沙利铂联合表柔比星经导管动脉栓塞化疗治疗原发性肝癌的临床疗效。方法根据治疗方法的不同将82例行经导管动脉栓塞化疗的原发性肝癌患者分为对照组(n=39,奥沙利铂联合吉西他滨治疗)和观察组(n=43,奥沙利铂联合表柔比星治疗)。比较两组患者的近期疗效、肿瘤标志物[癌胚抗原(CEA)、甲胎蛋白(AFP)]水平及不良反应发生情况。结果观察组患者的总有效率为83.72%,高于对照组患者的64.10%(P﹤0.05)。治疗后,两组患者的CEA、AFP水平均低于本组治疗前,且观察组患者的CEA、AFP水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为16.28%,低于对照组患者的35.90%(P﹤0.05)。结论奥沙利铂联合表柔比星经导管动脉栓塞化疗治疗原发性肝癌疗效确切,可有效降低患者的肿瘤标志物水平,且安全性较好,值得临床推广应用。Objective To investigate the clinical efficacy of oxaliplatin combined with epirubicin transcatheter arteri-al chemoembolization in the treatment of primary liver cancer.Method A total of 82 patients with primary liver cancer who received transcatheter arterial chemoembolization were divided into control group(n=39,oxaliplatin combined with gemcitabine treatment)and observation group(n=43,oxaliplatin combined with epirubicin treatment)according to differ-ent treatment regimens.The short-term efficacy,tumor markers[carcinoembryonic antigen(CEA),alpha fetoprotein(AFP)]levels,and adverse events were compared between the two groups.Result The total response rate in the observa-tion group was 83.72%,which was higher than that of 64.10%in the control group(P<0.05).After the treatment,the lev-els of CEA and AFP in the two groups were lower than those before the treatment,and the levels of CEA and AFP in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse events in the observation group was 16.28%,which was lower than that of 35.90%in the con-trol group(P<0.05).Conclusion Oxaliplatin combined with epirubicin transcatheter arterial chemoembolization in the treatment of primary liver cancer is effective.This regimen,which is worthy of clinical application,could effectively re-duce the level of tumor markers in patients,and has good safety.

关 键 词：原发性肝癌 奥沙利铂 表柔比星 癌胚抗原 甲胎蛋白 

分 类 号：R735.7[医药卫生—肿瘤]